CStone plans Phase I CS5007-101 trial in advanced solid tumors after IND filing

• CStone highlighted preclinical results for three antibody-drug conjugate candidates at AACR 2026, including lead program CS5007 targeting EGFR and HER3.
• Data presented showed CS5007 produced broad anti-tumor activity in laboratory and animal models, including activity in models designed to reflect treatment resistance.
• CStone outlined plans to file an IND for CS5007 in 1H 2026, setting up a Phase I monotherapy dose-escalation and expansion study in advanced solid tumors.
• Planned CS5007-101 trial targets enrollment of about 70 adult patients with advanced solid tumors.
• Separate IND filings were slated for CS5006 and CS5008 in 2H 2026, positioning multiple new oncology assets for clinical entry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260420-12111236), on April 20, 2026, and is solely responsible for the information contained therein.